Prescribe Cosentyx as your first-line biologic to give you confidence in lasting clear skin for your adult psoriasis patients
Superior results with Cosentyx
At week 16:
Cosentyx helps 21% more patients achieve almost clear skin vs. ustekinumab (P<0.0001)1
Confidence in lasting clear skin
Cosentyx maintains almost 100% of PASI 90 & PASI 100 response rates from year 1 to year 43
Comparable safety profile
Cosentyx has a comparable safety profile to etanercept and ustekinumab at week 524,5
No increase in adverse events over time, seen for between 1 to 4 years3
- Thaçi D, et al. J Am Acad Dermatol 2015; 73(3): 400–409.
- McInnes IB, et al. Poster presented at Rheumatology 2017, 25-27 April, 2017, Birmingham, United Kingdom. Poster number 072.
- Bissonnette R, et al. Secukinumab demonstrates sustained high efficacy and a favorable safety profile in moderate to severe psoriasis patients through 4 years of treatment. Oral presentation given at the 25th EADV Congress, 28 September–2 October 2016.
- Blauvelt A, et al. J Am Acad Dermatol 2017; 76(1): 60–69.
- Langley RG, et al. N Engl J Med 2014; 371(4): 326–338.
- Cosentyx Summary of Product Characteristics.
COS17-C172 August 2017